Minocycline/disodium edetate/ethyl alcohol - Citius Pharmaceuticals

Drug Profile

Minocycline/disodium edetate/ethyl alcohol - Citius Pharmaceuticals

Alternative Names: Mino-Lok; Mino-Lok Therapy (MLT); Minocycline-EDTA-EtOH

Latest Information Update: 26 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Citius Pharmaceuticals Inc; Leonard Meron Biosciences; University of Texas M. D. Anderson Cancer Center
  • Class Anti-infectives; Antibacterials; Anticoagulants; Antiseptics; Disinfectants; Small molecules; Tetracyclines
  • Mechanism of Action Chelating agents; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Catheter infections

Most Recent Events

  • 24 Jul 2018 University of Texas M. D. Anderson Cancer Center receives patent allowance for enhanced stability of minocycline/disodium edetate/ethyl alcohol in USA
  • 19 Jun 2018 Citius Pharmaceuticals announces intention to complete a pivotal phase III trial and submit NDA to the US FDA for Catheter infections in 2019
  • 15 Feb 2018 Citius Pharmaceuticals enrolls first patient in the phase III trial in Catheter infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top